金斯瑞生物科技(01548.HK)：传奇宣布于2025年ASH年会上公布报告

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate company, Legend Biotech, presented significant clinical data at the 2025 American Society of Hematology (ASH) annual meeting, highlighting the long-term follow-up results of CARVYKTI in patients with relapsed or refractory multiple myeloma (RRMM) [1] Group 1 - Legend Biotech released a press statement on December 6, 2025, detailing the CARTITUDE-1 and CARTITUDE-4 studies, which focus on CARVYKTI's efficacy in RRMM patients [1] - The presentation included the latest results from the Phase III CARTITUDE-4 study, showcasing the durability of response data across different subgroups and real-world studies [1] - Additionally, Legend Biotech introduced initial human trial data for its dual-target allogeneic CAR-T candidate product, LUCAR-G39D, during the ASH meeting [1]